NCT04842266
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting

Drug Category: Other

Key Eligibility Criteria:

Gender: All
Age: 21 Years and older (Adult, Older Adult)
Location of Metastases: Bone
Additional Notes: Patient must have at least one metastatic lesion of the pelvis
Exclusions: Patients with neurologic deficits as a result of metastases in the brain, spine, or other central nervous system disorders
https://ClinicalTrials.gov/show/NCT04842266